$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000117887920000033 Filed on August 10, 2020

Income Statement

Concept	2020 Q2	2019 Q2	2019 Q1
Revenue	$62.35M	$44.13M	$34.05M
YoY Change	41.29%	107.1%	103.92%
Cost Of Revenue	$6.676M	$5.367M	$4.055M
YoY Change	24.39%	71.2%	55.07%
Gross Profit	$55.68M	$38.76M	$29.99M
YoY Change	43.63%	113.29%	112.99%
Gross Profit Margin	89.29%	87.84%	88.09%
Selling, General & Admin	$34.66M	$42.58M	$44.30M
YoY Change	-18.6%	45.96%	61.71%
% of Gross Profit	62.25%	109.84%	147.72%
Research & Development	$69.61M	$70.98M	$64.59M
YoY Change	-1.93%	104.79%	58.32%
% of Gross Profit	125.03%	183.12%	215.37%
Depreciation & Amortization	$2.039M	$1.154M	$991.0K
YoY Change	76.69%	18.6%	2.27%
% of Gross Profit	3.66%	2.98%	3.3%
Operating Expenses	$107.0M	$115.2M	$111.3M
YoY Change	-7.09%	76.93%	58.36%
Operating Profit	-$51.35M	-$76.43M	-$81.28M
YoY Change	-32.82%	62.86%	44.67%
Interest Expense	$3.635M	$4.625M	$6.454M
YoY Change	-21.41%	1.43%	43.81%
% of Operating Profit
Other Income/Expense, Net	$5.326M	-$877.0K	$1.086M
YoY Change	-707.3%	-83.5%	-60.71%
Pretax Income	-$48.79M	-$83.83M	-$120.1M
YoY Change	-41.8%	36.33%	134.14%
Income Tax	$3.703M	$717.0K	$168.0K
% Of Pretax Income
Net Earnings	-$52.49M	-$84.55M	-$120.3M
YoY Change	-37.92%	36.74%	141.0%
Net Earnings / Revenue	-84.19%	-191.6%	-353.34%
Basic Earnings Per Share	-$0.20
Diluted Earnings Per Share	-$0.20	-$355.1K	-$563.4K
COMMON SHARES
Basic Shares Outstanding	258.0M shares	230.5M shares	223.7M shares
Diluted Shares Outstanding	258.0M shares

Balance Sheet

Concept	2020 Q2	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$309.6M	$575.7M	$438.3M
YoY Change	-46.22%	6.81%	-22.08%
Cash & Equivalents	$164.6M	$220.6M	$96.35M
Short-Term Investments	$145.0M	$355.1M	$342.0M
Other Short-Term Assets	$18.30M	$20.10M	$13.60M
YoY Change	-8.96%	737.5%	28.3%
Inventory	$12.98M	$10.40M	$8.167M
Prepaid Expenses
Receivables	$43.04M	$28.71M	$22.96M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$383.9M	$634.9M	$483.0M
YoY Change	-39.53%	10.18%	-18.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.95M	$15.27M	$13.29M
YoY Change	207.37%	67.63%	49.28%
Goodwill	$197.8M	$197.8M	$197.8M
YoY Change	0.0%	0.0%
Intangibles	$23.00M	$23.00M	$23.00M
YoY Change	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$25.88M	$12.04M	$11.27M
YoY Change	115.01%	103.47%	101.16%
Total Long-Term Assets	$317.6M	$283.2M	$281.7M
YoY Change	12.15%	13.42%	1.32%
TOTAL ASSETS
Total Short-Term Assets	$383.9M	$634.9M	$483.0M
Total Long-Term Assets	$317.6M	$283.2M	$281.7M
Total Assets	$701.5M	$918.0M	$764.7M
YoY Change	-23.59%	11.16%	-12.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.31M	$84.10M	$60.60M
YoY Change	-82.99%	102.16%	38.67%
Accrued Expenses	$94.00M	$2.700M	$2.500M
YoY Change	3381.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$108.3M	$89.55M	$65.87M
YoY Change	20.94%	69.07%	-53.18%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0M	$149.1M	$168.8M
YoY Change	0.6%	-11.98%	1.2%
Other Long-Term Liabilities	$4.511M	$3.987M	$3.609M
YoY Change	13.14%	43.94%	-89.54%
Total Long-Term Liabilities	$4.511M	$3.987M	$3.609M
YoY Change	13.14%	43.94%	-98.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$108.3M	$89.55M	$65.87M
Total Long-Term Liabilities	$4.511M	$3.987M	$3.609M
Total Liabilities	$340.5M	$318.0M	$313.0M
YoY Change	7.08%	20.45%	-10.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.900B	-$1.600B	-$1.533B
YoY Change	18.75%	36.17%	-400236.03%
Common Stock	$2.253B	$2.204B	$1.973B
YoY Change	2.24%	27.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$361.0M	$600.1M	$451.7M
YoY Change
Total Liabilities & Shareholders Equity	$701.5M	$918.0M	$764.7M
YoY Change	-23.59%	11.16%	-12.1%

Cashflow Statement

Concept	2020 Q2	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$52.49M	-$84.55M	-$120.3M
YoY Change	-37.92%	36.74%	141.0%
Depreciation, Depletion And Amortization	$2.039M	$1.154M	$991.0K
YoY Change	76.69%	18.6%	2.27%
Cash From Operating Activities	-$33.52M	-$58.48M	-$78.55M
YoY Change	-42.68%	2.6%	58.61%
INVESTING ACTIVITIES
Capital Expenditures	-$1.070M	-$2.170M	$2.944M
YoY Change	-50.69%	104.72%	259.46%
Acquisitions
YoY Change
Other Investing Activities	$71.08M	-$12.90M	$83.01M
YoY Change	-651.01%	-209.51%	-145.67%
Cash From Investing Activities	$70.01M	-$15.07M	$80.07M
YoY Change	-564.57%	-240.58%	-143.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$189.0M	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.090M	196.4M	$17.38M
YoY Change	-97.92%	2693.88%	-94.14%
NET CHANGE
Cash From Operating Activities	-33.52M	-58.48M	-$78.55M
Cash From Investing Activities	70.01M	-15.07M	$80.07M
Cash From Financing Activities	4.090M	196.4M	$17.38M
Net Change In Cash	40.58M	122.9M	$16.55M
YoY Change	-66.97%	-413.02%	-74.66%
FREE CASH FLOW
Cash From Operating Activities	-$33.52M	-$58.48M	-$78.55M
Capital Expenditures	-$1.070M	-$2.170M	$2.944M
Free Cash Flow	-$32.45M	-$56.31M	-$81.49M
YoY Change	-42.37%	0.66%	61.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33497
	dei	Entity Registrant Name EntityRegistrantName	Amicus Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	71-0869350
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Cedar Brook Drive,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
	dei	City Area Code CityAreaCode	(609)
	dei	Local Phone Number LocalPhoneNumber	662-2000
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	FOLD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	258787743	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164573000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2020Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	145017000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	309903000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43040000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33284000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	12979000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	14041000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18275000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20008000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	383884000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	520073000	USD
CY2020Q2	fold	Accumulated Depreciation And Amortization Finance And Operating Right Of Use Leases AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases	6219000	USD
CY2019Q4	fold	Accumulated Depreciation And Amortization Finance And Operating Right Of Use Leases AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases	5342000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23949000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33315000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21194000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17604000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46945000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47705000	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	197797000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25876000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28317000	USD
CY2020Q2	us-gaap	Assets Assets	701451000	USD
CY2019Q4	us-gaap	Assets Assets	850207000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	14306000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21722000	USD
CY2020Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	85478000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	99901000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8516000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7189000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	108300000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	128812000	USD
CY2020Q2	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	8906000	USD
CY2019Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	8906000	USD
CY2020Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2203000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2131000	USD
CY2020Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	147834000	USD
CY2019Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	147374000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	20027000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22681000	USD
CY2020Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5051000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5051000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43666000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53531000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4511000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5296000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	340498000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	373782000	USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	258223842	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	255417869	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	258223842	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	255417869	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	2614000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	2598000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2250849000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2227225000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	4865000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	2785000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	288000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	40000	USD
CY2020Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12387000	USD
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12387000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1910050000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1768610000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	360953000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	476425000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	701451000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	850207000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	62353000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	44130000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	122878000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	78176000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6676000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5367000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13228000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9422000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	55677000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	38763000	USD
	us-gaap	Gross Profit GrossProfit	109650000	USD
	us-gaap	Gross Profit GrossProfit	68754000	USD
CY2020Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	69611000	USD
CY2019Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	70981000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	158731000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	135574000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34657000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42578000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	74872000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86881000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-715000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-480000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1646000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1863000	USD
CY2020Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2039000	USD
CY2019Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1154000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3803000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2145000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	107022000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	115193000	USD
	us-gaap	Operating Expenses OperatingExpenses	239052000	USD
	us-gaap	Operating Expenses OperatingExpenses	226463000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-51345000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-76430000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-129402000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-157709000	USD
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	865000	USD
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	2599000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2380000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5238000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	3635000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	4625000	USD
	us-gaap	Interest Expense InterestExpense	7364000	USD
	us-gaap	Interest Expense InterestExpense	11079000	USD
CY2020Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4501000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-40624000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5326000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-877000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2990000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	209000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	885000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48789000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83834000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-137376000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-203965000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3703000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	717000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4064000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-52492000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-84551000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-141440000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-204850000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	257973329	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	238089824	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	257548623	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	225848013	shares
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-52492000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-84551000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-141440000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-204850000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-2090000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	30000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-554000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	30000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2116000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1881000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2080000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	77000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	122000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	220000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	66000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	220000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	457000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-22000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	248000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	562000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1659000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1859000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2328000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	639000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54151000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-82692000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-139112000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-204211000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	402594000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4656000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-554000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8408000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	457000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2116000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-52492000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	360953000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	476425000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10733000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-8097000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	21004000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	248000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2080000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-141440000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	360953000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	451668000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2807000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	188994000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-615000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	9935000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	24718000	USD
CY2019Q2	fold	Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations	5243000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-22000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1881000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-84551000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	600058000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	342912000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6760000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	188994000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-2555000	USD
	fold	Stock Issued During Period Value Contingent Consideration StockIssuedDuringPeriodValueContingentConsideration	9316000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	22679000	USD
	fold	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	812000	USD
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	215476000	USD
	fold	Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations	19875000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	562000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	77000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-204850000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	600058000	USD
	us-gaap	Profit Loss ProfitLoss	-141440000	USD
	us-gaap	Profit Loss ProfitLoss	-204850000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	532000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2104000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3803000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2145000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21004000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	22679000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-40624000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1646000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1863000	USD
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-5604000	USD
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-530000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10388000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6829000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1351000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1908000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1375000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3523000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-23916000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12453000	USD
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-1031000	USD
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-819000	USD
	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	0	USD
	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-1500000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-141460000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-137031000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	191318000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1876000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5110000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	210139000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	261425000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	45005000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	163258000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	64997000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	188994000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	38000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	98000	USD
	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	8097000	USD
	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	2555000	USD
	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	0	USD
	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	19875000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10734000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6760000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	812000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2599000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	213788000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3476000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-941000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20921000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	140813000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146341000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82375000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167262000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	223188000	USD
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	455000	USD
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	10709000	USD
	us-gaap	Interest Paid Net InterestPaidNet	9302000	USD
	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	0	USD
	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	9316000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	502000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	837000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1900000000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of June 30, 2020 and through the issuance of this report. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">®</sup>. The Company's accounts receivable at June 30, 2020 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers and the geographic economic environments and conditions to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	62353000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	44130000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	122878000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	78176000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164600000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	145000000.0	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164573000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	164573000	USD
CY2020Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	309104000	USD
CY2020Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	490000	USD
CY2020Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2020Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	309590000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164573000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	164573000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	144531000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	490000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	145017000	USD
CY2020Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	309104000	USD
CY2020Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	490000	USD
CY2020Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2020Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	309590000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	142837000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	452502000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	452740000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	142837000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	309665000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	309903000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	452502000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	452740000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	9500000	USD
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2019	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	17700000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	42600000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164573000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3837000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	220578000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2689000	USD
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2610000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167262000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	223188000	USD
CY2020Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1872000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6544000	USD
CY2020Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4571000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3660000	USD
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6536000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	12979000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	14041000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2020Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2019Q2	fold	Debt Instrument Convertible Debt Exchange Agreement Aggregate Principal Amount DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount	247200000	USD
CY2019Q2	fold	Debt Instrument Convertible Debt Exchange Agreement Shares Authorized For Issuance DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance	44000000.0	shares
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	fold	Debt Instrument Convertible Debt Exchange Agreement Accrued And Unpaid Interest DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest	1300000	USD
CY2019Q2	fold	Gain Loss On Extinguishment Of Debt Additional Paid In Capital GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital	215000000.0	USD
CY2019Q2	fold	Gain Loss On Extinguishment Of Debt Fair Value Of Common Shares Issued GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued	400000	USD
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-36100000	USD
CY2019Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4500000	USD
	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	19900000	USD
CY2020Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3410000	USD
CY2019Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4146000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6995000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	8959000	USD
CY2020Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	268000	USD
CY2019Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	423000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	474000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1982000	USD
CY2020Q2	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	33000	USD
CY2019Q2	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	39000	USD
	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	58000	USD
	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	122000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8408000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9935000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21004000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22679000	USD
CY2020Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	148251000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	24327000	USD
CY2020Q2	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	3312000	USD
CY2020Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	27639000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	314270000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	22681000	USD
CY2019Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	4419000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	27100000	USD
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	23612000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20767000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22681000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19700000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-715000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-480000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1646000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1863000	USD
CY2020Q2	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	0	USD
CY2019Q2	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	0	USD
	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	0	USD
	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	-316000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	24327000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21247000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	24327000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21247000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-52492000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-84551000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-141440000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-204850000	USD
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	257973329	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	238089824	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	257548623	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	225848013	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28915000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26751000	shares

Files In Submission

Name	View Source	Status
0001178879-20-000033-index-headers.html	Edgar Link	pending
0001178879-20-000033-index.html	Edgar Link	pending
0001178879-20-000033.txt	Edgar Link	pending
0001178879-20-000033-xbrl.zip	Edgar Link	pending
a1cbdleasetermletter26.htm	Edgar Link	pending
amicus-xloanagreemente.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fold-06302020xex311.htm	Edgar Link	pending
fold-06302020xex312.htm	Edgar Link	pending
fold-06302020xex321.htm	Edgar Link	pending
fold-20200630.htm	Edgar Link	pending
fold-20200630.xsd	Edgar Link	pending
fold-20200630_cal.xml	Edgar Link	unprocessable
fold-20200630_def.xml	Edgar Link	unprocessable
fold-20200630_htm.xml	Edgar Link	completed
fold-20200630_lab.xml	Edgar Link	unprocessable
fold-20200630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2020 Q2 Form 10-Q Financial Statement

#000117887920000033 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2020 Q2 Form 10-Q Financial Statement

#000117887920000033 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold